PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Semaglutide - Diabetes Mellitus

PAD Profile : Semaglutide - Diabetes Mellitus

Keywords :
GLP-1s, GLP1s, GLP 1s, glucagon like peptide-1, blood glucose lowering drugs, Type II
Brand Names Include :
Ozempic, Rybelsus

Traffic Light Status

Status 1 of 2.

Status :
Green (see narrative)
Important
Formulations :
  • Subcutaneous injection (sc)
Important Information :
Dulaglutide is 1st line. Semaglutide is the 2nd line option for WEEKLY injection. Max of 13 Ozempic pens per patient per year (1 pen is a 4 week supply).
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Green (see narrative)
Important
Formulations :
  • Tablets
Important Information :
Oral semaglutide is not a preferred route due to poor availability and gastrointestinal side effects. Use may be appropriate in a small cohort of patients where injection isn't suitable.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
03 May 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Do not prescribe Ozempic® for the treatment of obesity.

Weight Management Guidelines - for advice see Guidelines : Weight management in adults (res-systems.net)

02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Dulaglutide continues to be the preferred GLP-1 where weekly injection is indicated (due to it no longer having black triangle status)

Semaglutide is an alternative option for weekly injection. Do not prescribe more than a maximum of 13 Ozempic® pens per year for people with Type II Diabetes 

Liraglutide is an alternative 1st-line (for patients who wish to have a daily injection)

Lixisenatide is no longer a preferred treatment but remains an option.

Treatment with GLP-1s should be reviewed at 6 months. If there is no beneficial metabolic response (defined in NICE guidance), then stop treatment, and consider alternative treatment (usually insulin initiation) in line with NICE guidance

 

Associated BNF Codes

06. Endocrine System
06.01.02. Antidiabetic drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More